Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 9/20 | 0.52 |
| ▸ | SDC2 | P34741 | 9/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765599 | 1.00 | SDCBP (0.52) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765504 | 1.00 | SDCBP (0.52) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2177896 | 0.89 | SDCBP (0.65) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2179877 | 0.86 | SDCBP (0.62) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL17141805 | 0.85 | SDCBP (0.46) | SDCBPSDC2MAPTALDH1A1THRB | |
| SCHEMBL2180875 | 0.84 | SDCBP (0.51) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765807 | 0.83 | ALOX15 (0.50) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18765805 | 0.83 | ALOX15 (0.50) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL18086772 | 0.83 | SDCBP (0.45) | SDCBPSDC2TDP1L3MBTL1THRB | |
| SCHEMBL18794099 | 0.82 | SDCBP (0.42) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| EP-4352052-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117881676-A | Methods for preparing ERK inhibitors | 大塚制药株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2022259222-A1 | PROCESS FOR PREPARING AN ERK INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-15 | — | — | WO | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-110831939-A | 6-pyrimidine-isoindole derivatives as ERK1/2 inhibitors | 大冢制药株式会社 | 2020-02-21 | — | — | CN | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2018193410-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-10-25 | — | — | WO | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SDCBP 4433/4885SDC2 4006/4885ALOX15 1376/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | MAPKAPK2, MAP4K2, MAPK1 | SDCBP 4450/4885SDC2 4030/4885ALOX15 4598/4885 |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | MAPKAPK2, MAP4K2, MAPK1 | SDCBP 4450/4885SDC2 4030/4885ALOX15 4598/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SDCBP 4427/4885SDC2 4003/4885ALOX15 1370/4885 |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | SDCBP 2373/4885SDC2 3855/4885ALOX15 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.